Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH

被引:317
|
作者
Pierantonelli, Irene [1 ]
Svegliati-Baroni, Gianluca [1 ,2 ]
机构
[1] Univ Politecn Marche, Dept Gastroenterol, Via Tronto 10, I-60126 Ancona, Italy
[2] Univ Politecn Marche, Obes Ctr, Ancona, Italy
关键词
ENDOPLASMIC-RETICULUM STRESS; ALLEVIATES INSULIN-RESISTANCE; ADIPOSE TRIGLYCERIDE LIPASE; UNFOLDED PROTEIN RESPONSE; GUT MICROBIOTA; OXIDATIVE STRESS; HEPATOCELLULAR-CARCINOMA; HEPATIC STEATOSIS; LIPID-METABOLISM; FREE-CHOLESTEROL;
D O I
10.1097/TP.0000000000002480
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) represents a growing cause of chronic liver injury, especially in western countries, where it is becoming the most frequent indication for liver transplantation. Nonalcoholic fatty liver disease encompasses a spectrum of diseases that from simple steatosis (pure NAFLD) can progress to nonalcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. The pathogenesis of NAFLD and the mechanisms behind its progression to NASH have been extensively studied. However, although the processes that determine fat accumulation are mostly clear, the mechanisms associated with the progression of the disease are not fully characterized. In predisposed patients, lipid accumulation can promote lipotoxicity and mitochondrial dysfunction, thus triggering hepatocyte death, inflammation and fibrosis. The specific role of different lipids has been identified and free fatty acids as well as free cholesterol have been identified as toxic species. To make the picture more complex, the pathogenesis of NAFLD involves pathological connections between several organs, including the adipose tissue and the gut, with the liver. The "inflamed" adipose tissue plays a key role in the release of toxic lipids, whereas alterations in the gut-liver axis have been associated with the progression from NAFLD to NASH mediated by dysbiosis, alteration of intestinal barrier, and finally bacterial translocation, which can trigger proinflammatory and profibrogenetic pathways, finally leading to cirrhosis development.
引用
收藏
页码:e1 / e13
页数:13
相关论文
共 50 条
  • [41] Developmental Origins of Nonalcoholic Fatty Liver Disease (NAFLD)
    Itoh, Hiroaki
    Kanayama, Naohiro
    DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE (DOHAD): FROM BIOLOGICAL BASIS TO CLINICAL SIGNIFICANCE, 2018, 1012 : 29 - 39
  • [42] Vitamin E and nonalcoholic fatty liver disease (NAFLD)
    Thakur, Varsha
    Ulatowski, Lynn
    Parker, Robert
    Zhang, Renliang
    Liu, Xiuli
    Manor, Danny
    FASEB JOURNAL, 2013, 27
  • [43] Nutritional Management of Nonalcoholic fatty liver disease (NAFLD)
    Boudaoud, Amel Ait
    Rives-Lange, Claire
    Perregaux, Jean Francois
    Radu, Alina
    Messager-Josipowicz, Diane
    Barsamian, Charles
    Carette, Claire
    Czernichow, Sebastien
    PRESSE MEDICALE, 2019, 48 (12): : 1496 - 1501
  • [44] Intestinal permeability in nonalcoholic fatty liver disease (NAFLD).
    Miele, L
    Valenza, V
    Mascianà, R
    Gabrieli, ML
    Perotti, G
    Cammarota, G
    Montalto, M
    Forgione, A
    Vero, V
    Gasbarrini, G
    Grieco, A
    HEPATOLOGY, 2004, 40 (04) : 585A - 585A
  • [45] Role of plasma FGF21 as a biomarker for nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH)
    Bril, Fernando
    Lomonaco, Romina
    Orsak, Beverly
    Chang, Zhi
    Ortiz-Lopez, Carolina
    Hecht, Joan
    Tio, Fermin
    Cusi, Kenneth
    HEPATOLOGY, 2013, 58 : 487A - 487A
  • [46] Endoplasmic Reticulum Stress Related Molecular Mechanisms in Nonalcoholic Fatty Liver Disease (NAFLD)
    Wang, Lifeng
    Chen, Junhua
    Ning, Chao
    Lei, Dongyu
    Ren, Jun
    CURRENT DRUG TARGETS, 2018, 19 (09) : 1087 - 1094
  • [47] Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
    Wen, Xuerong
    Wang, Shuang
    Taveira, Tracey H.
    Akhlaghi, Fatemeh
    PLOS ONE, 2021, 16 (09):
  • [48] Effect of Roux-en-Y Reconstruction on Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH)
    Kashihara, Hideya
    Yoshikawa, Kozo
    Higashijima, Jun
    Nishi, Masaaki
    Takasu, Chie
    Shimada, Mitsuo
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2017, 225 (04) : E58 - E59
  • [49] Therapeutic Effects of microRNAs on Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis
    Zhu, Yuezhi
    Tan, Jen Kit
    Wong, Sok Kuan
    Goon, Jo Aan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (11)
  • [50] Assessment of Imaging Modalities Against Liver Biopsy in Nonalcoholic Fatty Liver Disease: The Amsterdam NAFLD-NASH Cohort
    Troelstra, Marian A.
    Witjes, Julia J.
    van Dijk, Anne-Marieke
    Mak, Anne L.
    Gurney-Champion, Oliver
    Runge, Jurgen H.
    Zwirs, Diona
    Stols-Goncalves, Daniela
    Zwinderman, Aelko H.
    ten Wolde, Marije
    Monajemi, Houshang
    Ramsoekh, Sandjai
    Sinkus, Ralph
    van Delden, Otto M.
    Beuers, Ulrich H.
    Verheij, Joanne
    Nieuwdorp, Max
    Nederveen, Aart J.
    Holleboom, Adriaan G.
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2021, 54 (06) : 1937 - 1949